Fusion Pharmaceuticals Inc (DELISTED) (FUSN:DL)
21.55
0.00 (0.00%)
USD |
NASDAQ |
Jun 04, 16:00
Fusion Pharmaceuticals SG&A Expense (Quarterly): 14.55M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 14.55M |
December 31, 2023 | 7.628M |
September 30, 2023 | 6.81M |
June 30, 2023 | 7.753M |
March 31, 2023 | 9.006M |
December 31, 2022 | 6.95M |
September 30, 2022 | 7.42M |
June 30, 2022 | 7.781M |
March 31, 2022 | 8.449M |
December 31, 2021 | 6.336M |
September 30, 2021 | 7.156M |
Date | Value |
---|---|
June 30, 2021 | 6.642M |
March 31, 2021 | 6.964M |
December 31, 2020 | 6.639M |
September 30, 2020 | 5.79M |
June 30, 2020 | 3.988M |
March 31, 2020 | 4.327M |
December 31, 2019 | 2.724M |
September 30, 2019 | 1.922M |
June 30, 2019 | 1.771M |
March 31, 2019 | 1.171M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.922M
Minimum
Sep 2019
14.55M
Maximum
Mar 2024
6.781M
Average
6.95M
Median
Dec 2022
SG&A Expense (Quarterly) Benchmarks
AstraZeneca PLC | 5.061B |
Landos Biopharma Inc (DELISTED) | 6.144M |
Acasti Pharma Inc | 2.254M |
Aurinia Pharmaceuticals Inc | 42.28M |
Edesa Biotech Inc | 1.035M |